Mylan strikes Humira biosim delay deal with AbbVie

Jul 20, 2018

In an effort to protect its Humira patent, AbbVie signed an agreement to grant Mylan the rights to begin marketing its biosimilar in the United States in 2023.

In 2017, Humira generated more than $18 billion for AbbVie – about two-thirds of the company's total revenue.

Mylan's U.S. license will begin on July 31, 2023. Mylan will pay royalties to AbbVie for licensing its Humira patents once its biosimilar product is launched. AbbVie has struck similar deals with Amgen and Samsung Bioepis. The settlements give AbbVie more time to strengthen its pipeline with products that are capable of making up for the expected sales decline when Humira biosimilars are launched.

Read the press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments